Bradly G. Wouters

Inception 5, Inc. develops and researches novel small molecule demyelinating therapies for patients with multiple sclerosis. The company is headquartered in San Diego, CA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.

Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life.

Iaculor Injection, Inc. develops needle free medical devices. It engages in the development and commercialization of needle-free medical devices for injecting drugs and vaccines. The company was founded by Martin Brouillette and is headquartered in Sherbrooke, Canada.

Part of GSK Plc, Okairos SRL is an Italian company that manufactures drugs. The company is based in Rome, Italy.

Neusentis Ltd. engages in other business support service activities. The company was founded on October 2, 1997 and is headquartered in Sandwich, the United Kingdom.

Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain.

Blueline Bioscience acts as an alternative investment manager. The company is headquartered in Toronto, Canada.

Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada.

Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA.

Versant Venture Capital VI (Canada) LP operates as a pooled investment fund. The company is headquartered in San Francisco, CA.

Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada.

Asabys Partners SGEIC SA (Asabys Partners) is an independent venture capital firm founded in 2019 by Clara Campàs-Moya and Josep Lluís Sanfeliu Benet. The firm is headquartered in Barcelona, Spain.

Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA.

Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada.

Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA.

Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA.

Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020.

Santa Ana Bio, Inc. is a biotechnology company that specializes in precision immunology for autoimmune diseases. The company is based in Alameda, CA. The CEO of the company is Peter Emtage.

Nuage Therapeutics SL is a biotech company located in Barcelona, ES. The company's address is Parc Científic de Barcelona C/ Baldiri Reixac 4-8 (Torre D) 08028 Barcelona. The company also has a chief financial officer who holds a PhD in biology from the University of Barcelona and an MBA from Duke University. Nuage Therapeutics specializes in careers for data scientists, lab technicians in protein purification and cell biology. The Spanish company's founders include Xavier Salvatella, an ICREA professor and leader of the Laboratory of Molecular Biophysics at IRB Barcelona, and Mateusz Besiaga, a PhD student and MSCA fellow in the Laboratory of Molecular Biophysics at IRB Barcelona. The company's team includes experts in transcriptional control, nuclear condensates, genome structure, genetics, developmental biology, and biomedical research. The company was founded in 2021, and Judit Anido Folgueira has been the CEO of the company since 2022.

Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov.